PEDIATRICS Vol. 107 No. 2 February 2001, pp. 293-298
Fluconazole for Prophylaxis Against Candidal Rectal Colonization in the Very Low Birth Weight Infant
Received Mar 7, 2000; accepted Jun 20, 2000.
,
From * Wake Medical Center, Raleigh, North Carolina; Hennepin
County Medical Center, Minnesota, Minneapolis, Minnesota; and
§ Department of Pediatrics, Medical University of South Carolina,
Charleston, South Carolina.
Background. Candidal infections are an important cause of morbidity and mortality in the very low birth weight (VLBW) infant. Current intervention focuses on treatment once candidal septicemia is either suspected or diagnosed. Studies have suggested that colonization with candidal species is an important risk factor for subsequent infection.
Objective. To determine whether prophylactic fluconazole for the first 28 days of life results in a decreased incidence of candidal colonization in the VLBW infant.
Research Design. Prospective, randomized, controlled, intention-to-treat design comparing prophylaxis with fluconazole versus placebo for the first 28 days of life.
Setting. A tertiary level intensive care nursery in a major teaching hospital in Charleston, South Carolina.
Patients. One hundred three infants with a birth weight of <1500 g, either inborn or outborn, who were admitted to the intensive care nursery between January 1998 and February 1999.
Methods. Infants were enrolled within 72 hours of life with rectal cultures performed on the day of randomization (DOR), as well as day of life (DOL) 7, 14, and 28. Those infants with a birth weight of <1250 g had additional cultures on DOL 35, 49, and 56. Cultures were plated on selective media for isolation of candidal organisms. Infants were randomized to receive either fluconazole (6 mg/kg) or placebo on the DOR. Subsequent doses were given every 72 hours until DOL 7 and then every 24 hours until DOL 28. Medication was given either intravenously or by feeding tube once the infant had been gavage feeding for a 48-hour period without feeding intolerance. Aspartate aminotransferase and alanine aminotransferase levels were obtained on DOR and DOL 7, 14, and 28 to assess for fluconazole toxicity. The minimal inhibitory concentration to fluconazole was determined for all positive cultures to assess the development of resistance.
Results. The infants who received fluconazole (n = 53) and placebo (n = 50) had no statistical difference in the major risk factors known to increase the chances of candidal septicemia in the VLBW infant. Rectal colonization by candidal species was detected in 8 of the 53 fluconazole-treated patients (15.1%) and in 23 of the 50 infants treated with placebo (46%). Fluconazole significantly reduced rectal colonization from DOL 14 through DOL 56 in all infants with a birth weight of <1250 g, and from DOL 14 through DOL 56 in all infants with a birth weight of 1250 to 1500 g. Alanine aminotransferase levels were higher in the fluconazole versus the placebo-treated group on DOL 14 (18.1 IU/L vs 15 IU/L), but no clinically significant abnormalities were observed. Candida albicans was the most common species isolated. There was no increase in species of Candida noted for their intrinsic resistance to fluconazole, and there was no statistically significant difference in the minimal inhibitory concentrations to fluconazole for all C albicans isolates in either group at any period.
Conclusion. Prophylactic administration of fluconazole to the VLBW infant for the first 28 days of life is safe and results in a decreased risk of rectal colonization by candidal species. Larger studies to determine the effect of prophylaxis on candidal septicemia and development of resistance in such a selective high-risk group are warranted before initiation of routine prophylaxis.fluconazole, very low birth weight infant, prophylaxis, candidal sepsis, sensitivities to fluconazole. .
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  A Howell, D Isaacs, R Halliday, and T. A. S. G. f. N. Infections Oral nystatin prophylaxis and neonatal fungal infections Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2009; 94(6): F429 - F433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Ganesan, S Harigopal, T Neal, and C W Yoxall Prophylactic oral nystatin for preterm babies under 33 weeks' gestation decreases fungal colonisation and invasive fungaemia Arch. Dis. Child. Fetal Neonatal Ed., July 1, 2009; 94(4): F275 - F278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Healy Fungal Prophylaxis in the Neonatal Intensive Care Unit NeoReviews, December 1, 2008; 9(12): e562 - e570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kaufman Fluconazole Prophylaxis Decreases the Combined Outcome of Invasive Candida Infections or Mortality in Preterm Infants Pediatrics, November 1, 2008; 122(5): 1158 - 1159. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Trofa, A. Gacser, and J. D. Nosanchuk Candida parapsilosis, an Emerging Fungal Pathogen Clin. Microbiol. Rev., October 1, 2008; 21(4): 606 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Clerihew, N Austin, and W McGuire Systemic antifungal prophylaxis for very low birthweight infants: a systematic review Arch. Dis. Child. Fetal Neonatal Ed., May 1, 2008; 93(3): F198 - F200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Healy, J. R. Campbell, E. Zaccaria, and C. J. Baker Fluconazole Prophylaxis in Extremely Low Birth Weight Neonates Reduces Invasive Candidiasis Mortality Rates Without Emergence of Fluconazole-Resistant Candida Species Pediatrics, April 1, 2008; 121(4): 703 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A McCrossan, E. McHenry, F. O'Neill, G. Ong, and D. G Sweet Selective fluconazole prophylaxis in high-risk babies to reduce invasive fungal infection Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2007; 92(6): F454 - F458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Manzoni, I. Stolfi, L. Pugni, L. Decembrino, C. Magnani, G. Vetrano, E. Tridapalli, G. Corona, C. Giovannozzi, D. Farina, et al. A Multicenter, Randomized Trial of Prophylactic Fluconazole in Preterm Neonates N. Engl. J. Med., June 14, 2007; 356(24): 2483 - 2495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Venkatesh, D. Pham, M. Fein, L. Kong, and L. E. Weisman Neonatal Coinfection Model of Coagulase-Negative Staphylococcus (Staphylococcus epidermidis) and Candida albicans: Fluconazole Prophylaxis Enhances Survival and Growth Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1240 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Manzoni, D. Farina, M. Leonessa, E. A. d'Oulx, P. Galletto, M. Mostert, R. Miniero, and G. Gomirato Risk Factors for Progression to Invasive Fungal Infection in Preterm Neonates With Fungal Colonization Pediatrics, December 1, 2006; 118(6): 2359 - 2364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Burwell, D. Kaufman, J. Blakely, B. J. Stoll, and S. K. Fridkin Antifungal Prophylaxis to Prevent Neonatal Candidiasis: A Survey of Perinatal Physician Practices Pediatrics, October 1, 2006; 118(4): e1019 - e1026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Uko, L. M. Soghier, M. Vega, J. Marsh, G. T. Reinersman, L. Herring, V. A. Dave, S. Nafday, and L. P. Brion Targeted Short-Term Fluconazole Prophylaxis Among Very Low Birth Weight and Extremely Low Birth Weight Infants Pediatrics, April 1, 2006; 117(4): 1243 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Charlier, E. Hart, A. Lefort, P. Ribaud, F. Dromer, D. W. Denning, and O. Lortholary Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J. Antimicrob. Chemother., March 1, 2006; 57(3): 384 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Benjamin Jr, B. J. Stoll, A. A. Fanaroff, S. A. McDonald, W. Oh, R. D. Higgins, S. Duara, K. Poole, A. Laptook, R. Goldberg, et al. Neonatal Candidiasis Among Extremely Low Birth Weight Infants: Risk Factors, Mortality Rates, and Neurodevelopmental Outcomes at 18 to 22 Months Pediatrics, January 1, 2006; 117(1): 84 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Fanaroff Fluconazole for the Prevention of Fungal Infections: Get Ready, Get Set, Caution Pediatrics, January 1, 2006; 117(1): 214 - 215. [Full Text] [PDF]
|
|
|
|
|
|
P. Manzoni, R. Arisio, M. Mostert, M. Leonessa, D. Farina, M. A. Latino, and G. Gomirato Prophylactic Fluconazole Is Effective in Preventing Fungal Colonization and Fungal Systemic Infections in Preterm Neonates: A Single-Center, 6-Year, Retrospective Cohort Study Pediatrics, January 1, 2006; 117(1): e22 - e32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sarvikivi, O. Lyytikainen, D. R. Soll, C. Pujol, M. A. Pfaller, M. Richardson, P. Koukila-Kahkola, P. Luukkainen, and H. Saxen Emergence of Fluconazole Resistance in a Candida parapsilosis Strain That Caused Infections in a Neonatal Intensive Care Unit J. Clin. Microbiol., June 1, 2005; 43(6): 2729 - 2735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kaufman and K. D. Fairchild Clinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants Clin. Microbiol. Rev., July 1, 2004; 17(3): 638 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Perinatal with allergy, immunity, and infection Arch. Dis. Child., April 1, 2004; 89(suppl_1): A32 - A33. [Full Text] [PDF]
|
|
|
|
|
|
D. K. Benjamin Jr, E. R. DeLong, W. J. Steinbach, C. M. Cotton, T. J. Walsh, and R. H. Clark Empirical Therapy for Neonatal Candidemia in Very Low Birth Weight Infants Pediatrics, September 1, 2003; 112(3): 543 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Kicklighter Antifungal Agents and Fungal Prophylaxis in the Neonate NeoReviews, December 1, 2002; 3(12): e249 - 255. [Full Text] [PDF]
|
|
|
|
|
|
C. Dani, G. Bertini, M. Pezzati, D. Casalaz, D. Kaufman, R. Boyle, and L. B. D. Grossman Fluconazole Prophylaxis against Fungal Infection in Preterm Infants N. Engl. J. Med., June 13, 2002; 346(24): 1913 - 1914. [Full Text] [PDF]
|
|
|
|
|
|
D. Kaufman, R. Boyle, K. C. Hazen, J. T. Patrie, M. Robinson, and L. G. Donowitz Fluconazole Prophylaxis against Fungal Colonization and Infection in Preterm Infants N. Engl. J. Med., December 6, 2001; 345(23): 1660 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Neely and J. R. Schreiber Fluconazole Prophylaxis in the Very Low Birth Weight Infant: Not Ready for Prime Time Pediatrics, February 1, 2001; 107(2): 404 - 405. [Full Text]
|
|
